Study of BioNIR Drug Eluting Stent System in Coronary Stenosis

Not Applicable

Completed

Conditions: Coronary Artery Stenosis

Interventions: Device: Resolute
Device: BioNIR

Registration Number: NCT01995487

Lead Sponsor: Medinol Ltd.

Brief Summary: The BioNIR study aims to show that the BioNIR ridaforolimus eluting stent is non-inferior to the Resolute zotarolimus-eluting stent for the primary clinical endpoint of target lesion failure (TLF) at 12 months; that it is non-inferior to the Resolute for the secondary endpoint of angiographic in-stent late loss at 13 months; and that it is more cost-effective.

Detailed Description: The BioNIR is a prospective, multi-center, single-blind, two-arm, randomized clinical trial. The population will consist of subjects undergoing PCI for angina (stable or unstable), silent ischemia, NSTEMI, and recent STEMI. Complex lesions are allowed. There is no limit to the number of lesions per vessel or individual lesion length; however, the total planned stenting in the coronary tree cannot exceed 100mm.

Randomization will be stratified by the presence of medically treated diabetes vs. no medically treated diabetes, acute coronary syndrome (ACS) vs. non-ACS, and by site. Lesions planned to be treated must be declared and recorded at time of randomization. Planned staged procedures, if necessary, must be declared immediately post procedure.

Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post randomization. 200 patients at participating North American sites will be consented for planned angiographic follow-up at 13 months after enrollment, with 100 of these patients consented to undergo planned IVUS at baseline and at 13 months following randomization.

The primary endpoint is Target Lesion Failure (TLF) at 12 months, defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.

Clinical Secondary Endpoints to be evaluated at 30 days, 6 months, and 1, 2, 3, 4 and 5, except as noted:

* Device, Lesion, and Procedure Success at time of baseline procedure

* TLF at 30 days, 6 months, and 2, 3, 4 and 5 years defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR.

* Major adverse cardiac events (MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR)

* Target vessel failure (TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR)

* All-cause mortality

* Cardiac death

* Myocardial Infarction

* Target Vessel Related MI

* Ischemia-driven TLR

* Ischemia-driven TVR

* Stent Thrombosis (ARC definite and probable)

Angiographic Sub-Study Secondary Endpoint to be evaluated at 13 months:

• Angiographic in-stent and in-segment late loss

IVUS Sub-Study Secondary Endpoint to be evaluated at 13 months:

* In-stent percent neointimal hyperplasia

* Stent mal-apposition

A key component of this trial will be a prospective assessment of health care resource utilization, costs and cost effectiveness. A separate cost effectiveness assessment plan describes the data collection and analysis.

Sample Size Consideration: From recent US trials of best in class DES (Xience V, Promus Element and Resolute), the 1-year TLF rate in patients with non-complex lesions not undergoing routine angiographic follow-up is approximately 3.8%. Using the assumption of the more-comers' design, the 1-year event rate will be conservatively increased by 50% (assuming enrollment rate for complex patients/lesions is 50% with double the standard event rate) - thus 5.8%. Therefore, with a one-sided 95% upper bound of the confidence interval of 3.3% (a relative 57% margin) and 1:1 randomization, enrolling 1810 patients (905 per group) provides 90% power to demonstrate non-inferiority. Assuming 95% follow-up rate at 1 year, approximately 1906 patients will be enrolled (953 in each group).

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1919

Inclusion Criteria

Patient with indication for PCI including angina/silent ischemia/NSTEMI/recent STEMI
Non-target vessel PCI allowed prior to randomization depending on time interval and certain conditions
Patient/legal guardian willing & able to provide informed written consent & comply with follow-up visits & testing schedule
Target lesion(s) must be located in native coronary artery/bypass graft conduit w/visually estimated diameter ≥2.5mm to ≤4.25mm.
Complex lesions allowed, including calcified, presence of thrombus, CTO, bifurcation (except as per exclusion criteria #30), ostial RCA, tortuous, bare metal stent restenotic, protected left main, and saphenous vein graft

Exclusion Criteria

STEMI within 24 hours of init. time of presentation to first treating hospital, or in whom enzyme levels (either CK-MB or Troponin) have not peaked
PCI within 24 hours preceding baseline procedure
Non-target lesion PCI in target vessel within 12 months of baseline procedure
History of stent thrombosis
Cardiogenic shock (persistent hypotension [systolic blood pressure <90mm/Hg for MT 30 min] or requiring pressors/hemodynamic support, including IABP)
Subject is intubated
Known LVEF <30%
Relative/absolute contraindication to DAPT for 12 months (including planned surgeries that cannot be delayed, or subject indicated for chronic oral anticoagulant treatment)
Calculated creatinine clearance <30 mL/min per Cockcroft-Gault equation (<40mL/min for subjects participating in angiographic follow-up sub-study)
Hemoglobin <10g/dL
Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
White blood cell (WBC) count <3,000 cells/mm3
Clinically significant liver disease
Active peptic ulcer/active bleeding from any site
Bleeding from any site within prior 8 wks requiring active medical/surgical attention
If femoral access is planned, significant peripheral arterial disease that precludes safe insertion of 6F sheath
History of bleeding diathesis/coagulopathy/will refuse blood transfusions
Cerebrovascular accident/transient ischemic attack within past 6 months, or any permanent neurologic defect attributed to CVA
Known allergy to study stent components, BioNIR or Resolute
Known allergy to protocol-required concomitant medications: aspirin/DAPT (clopidogrel, prasugrel, ticagrelor)/heparin and bivalirudin/iodinated contrast that cannot be adequately pre-medicated
Any co-morbid condition that may cause non-compliance with protocol (e.g. dementia, substance abuse) /reduced life expectancy to <24 months (e.g. cancer, severe heart failure, severe lung disease)
Patient participating/plans to participate in another investigational drug/device clinical trial that has not reached its primary endpoint
Pregnant/breastfeeding women (women of child-bearing potential must have a negative pregnancy test within 1 wk before treatment)
Women who intend to become pregnant within 12 months after baseline procedure (sexually active women of child-bearing potential must agree to use a reliable method of contraception from time of screening through 12 months post baseline procedure)
Patient has received/is on a waiting list for an organ transplant
Patient receiving/scheduled to receive chemotherapy within 30 days before/any time after the baseline procedure
Patient receiving oral/intravenous immunosuppressive therapy or has known life-limiting immunosuppressive/autoimmune disease (e.g. HIV); corticosteroids are allowed
More than 100mm length of planned stenting in the entire coronary tree
Unprotected left main lesions ≥30%, or planned left main intervention
Ostial LAD/LCX lesions (stenting of any diseased segment within 5mm of the unprotected left main coronary artery)
Bifurcation lesions with planned dual stent implantation
Stenting of lesions due to DES restenosis
Another lesion in a target/non-target vessel (including all side branches) is present that requires/has high probability of requiring PCI within 12 months after baseline procedure

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Resolute	Resolute	The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems: 1. Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent 2. Delivery system (Rapid Exchange \[RX\] Coronary System) 3. Polymer system 4. Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area.
BioNIR	BioNIR	The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising: * Stent - a mounted Cobalt Chromium (CoCr) alloy based stent * Delivery System - Rapid Exchange (RX) Coronary System * Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil® * Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent).

Primary Outcome Measures

Name	Time	Method
Target Lesion Failure (TLF)	12 months	The primary endpoint of TLF at 12 months was defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR.

Secondary Outcome Measures

Name	Time	Method
TLF	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical secondary endpoint to be evaluated at 30 days, 6 months, and 2, 3, 4 and 5 years, defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR
Target Vessel Related MI	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: The number of patients who suffer a MI that is related to the target vessel of the procedure.
Ischemia Driven TLR	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical:
Lesion Success	Determined at time of baseline procedure	Measures whether the lesion was successfully treated.
All Cause Mortality	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: The number of patients who die from all causes
Cardiac Death	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: The number of patients who die of cardiac-related causes
Angiographic Sub-Study: In-stent and In-segment Late Loss	13 months	Secondary Endpoint for angiographic in-stent and in-segment late loss
IVUS Sub-Study: In-stent Percent Neointimal Hyperplasia	13 months	IVUS: In-stent percent neointimal hyperplasia
Device Success	Determined at time of baseline procedure	Clinical: Acute secondary endpoint determined at time of baseline procedure
Target Vessel Failure	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR
Myocardial Infarction	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: The number of patients who suffer a myocardial infarction.
Ischemia Driven TVR	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical:
IVUS Sub-Study: Stent Mal-apposition	13 months	IVUS Sub-Study: Stent mal-apposition
Procedure Success	Determined at time of baseline procedure	Acute clinical endpoint: The success of the procedure as determined at time of baseline procedure
Major Adverse Cardiac Events	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR
Stent Thrombosis	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Clinical: ARC definite and probable

Trial Locations

Locations (8): Piedmont Healthcare
🇺🇸
Atlanta, Georgia, United States
Hospital Meixoeiro
🇪🇸
Pontevedra, Vigo, Spain
Hadassah Hebrew University Medical Center
🇮🇱
Jerusalem, Israel
San Raffaele Hospital
🇮🇹
Milan, Italy
ZNA Middelheim
🇧🇪
Antwerp, Belgium
Maasstad Ziekenhuis
🇳🇱
Rotterdam, Netherlands
PAKS, II Oddzial Kardiologiczny
🇵🇱
Bielsko-biala, Poland
Queen Elizabeth II Health Sciences Centre
🇨🇦
Halifax, Nova Scotia, Canada